BEUDAMED
    FDA Adverse Event Malfunction Summary report: N

    COBAS® TAQMAN® 48 ANALYZER

    MDR report key: 2000994 · Received February 24, 2011

    Report

    Report Number
    2243471-2011-00009
    Event Type
    Malfunction
    Date Received
    February 24, 2011
    Date of Event
    February 14, 2011
    Report Date
    February 24, 2011
    Manufacturer
    ROCHE DIAGNOSTICS, LTD.
    Product Code
    JJF
    PMA / PMN Number
    K012966
    Product Problem
    Yes
    Report Source
    Manufacturer report
    Reporter Occupation
    HEALTH PROFESSIONAL

    Narratives

    Additional Manufacturer Narrative · 1

    THIS ISSUE IS CURRENTLY UNDER INVESTIGATION. NO CONCLUSIONS CAN BE DRAWN AT THIS TIME. (B)(4).

    Additional Manufacturer Narrative · 1

    (B)(4) COMPUTER SOFTWARE PERFORMANCE TESTS CONDUCTED, ALGORITHM ANALYSIS, SOFTWARE / FIRMWARE CAUSED EVENT, UNUSUAL EVENT. THE INVESTIGATION DETERMINED THAT THE DISCREPANT TARGET NOT DETECTED (TND) RESULT WAS CAUSED BY THE BASELINE NORMALIZATION CALCULATION OF THE ELTH ALGORITHM. IN VERY RARE INSTANCES, THE ANALYSIS CURVES OF THE AFFECTED SAMPLES ARE NOISY IN THE FIRST FEW CYCLES. THE (B)(4) CURVES DID NOT HAVE ENOUGH VALID BASELINE POINTS FOR A CORRECT CALCULATION OF THE BASELINE. THEREFORE, THE DATA POINTS OF THE PLATEAU REGION WERE INCORRECTLY USED FOR THE CALCULATION OF THE BASELINE, LEADING TO AN INCORRECT TND RESULT. ALL AFFECTED ROCHE MOLECULAR SYSTEMS ASSAYS WERE ASSESSED FOR RISKS AND POSSIBLE IMPACTS DUE TO THE ELTH BASELINE NORMALIZATION ANOMALY. ALL POTENTIAL FAILURE MODES WERE ANALYZED. THE ANOMALY HAS AN EXTREMELY LOW RATE OF OCCURRENCE. (B)(4). ALL RESIDUAL RISKS IDENTIFIED WERE DETERMINED TO BE IN THE ACCEPTABLE OR ALARP (AS LOW AS REASONABLY PRACTICAL) RANGE. THE OVERALL RESIDUAL RISK WAS DETERMINED TO BE ACCEPTABLE WITH NO MAJOR IMPACT ON ASSAY OR SYSTEM PERFORMANCE EXPECTED. (B)(4).

    Description of Event or Problem · 1

    A CUSTOMER SITE IN (B)(6) REPORTED THAT THEY RECEIVED AN ERRONEOUS UNDER-QUANTIFIED RESULT WHEN USING THE COBAS TAQMAN (B)(6) TEST FOR USE WITH THE HIGH PURE SYSTEM TEST - (B)(6). THEIR INITIAL RESULT WAS TARGET NOT DETECTED (TND) BUT THE CUSTOMER RECOGNIZED THAT THE NORMALIZED AND UN-NORMALIZED ANALYSIS CURVES WERE DIFFERENT AND INDICATED THAT THE SAMPLE WAS A HIGH TITER SAMPLE. WHEN THE SAMPLE WAS RE-TESTED, IT GENERATED A VERY HIGH TITER RESULT - (B)(6).

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    1 COBAS® TAQMAN® 48 ANALYZER ANALYZER, CHEMISTRY, MICRO, FOR CLINICAL USE, PRODUCT CODE: JJF JJF ROCHE DIAGNOSTICS, LTD.

    Patients

    Seq Age Sex Outcome Treatment
    1